Effect of granulocyte colony-stimulating factor on outcomes inpatients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
- Authors
- Kang, Ka-Won; Kim, Dae Sik; Lee, Se Ryeon; Sung, Hwa Jung; Kim, Seok Jin; Choi, Chul Won; Kim, Byung Soo; Park, Yong
- Issue Date
- 6월-2017
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- Acute myelogenous leukemia; Granulocyte colony-stimulating factor; Neutropenia; Treatment-related mortality
- Citation
- LEUKEMIA RESEARCH, v.57, pp.1 - 8
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA RESEARCH
- Volume
- 57
- Start Page
- 1
- End Page
- 8
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/83278
- DOI
- 10.1016/j.leukres.2017.02.003
- ISSN
- 0145-2126
- Abstract
- We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML). Patients were classified as follows: no G-CSF administration during induction (no G-CSF group; 112 patients); administration immediately upon neutropenia onset (absolute neutrophil counts (ANC)<1000/mu L), but before febrile neutropenia (preemptive group; 74 patients); and administration following febrile neutropenia development (therapeutic group; 129 patients). G-CSF users had a shorter time to ANC recovery than the no G-CSF group (p<0.001). The chemotherapy-induced febrile neutropenia (CIFN) duration was significantly shorter in the preemptive group than in other groups (p<0.001). The incidence of CIFN was not significantly different between preemptive and non-G-CSF users (84.8% versus 82.4%). Preemptive G-CSF administration modestly improved treatment-related mortality (TRM), compared with no G-CSF administration (p=0.076 in multivariate analysis). G-CSF administration did not affect relapse-free or overall survivals or the cumulative relapse incidence among the groups. In conclusion, preemptive G-CSF administration reduced CIFN duration and modestly improved TRM without affecting chemotherapy outcomes. These effects were not observed in the therapeutic group; therefore, initiation of G-CSF during induction therapy before the development of febrile neutropenia may be desirable. (C) 2017 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.